Search filters

Filters
Clear All

Phase

  • 5
  • 3
  • 6
  • 7
  • 1
  • 37
  • 61
  • 35
  • 1
  • 60

Found 61 Lung Disease trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Cystic Fibrosis Microbiome
18-99 years
All genders
Among lung transplant recipients who survive to 5 years, half suffer from chronic lung allograft dysfunction (CLAD). This study will evaluate how changes in the lung microbiome may cause CLAD in Cystic Fibrosis patients who have been transplanted. This is a case-control study of Cystic Fibrosis lung transplant recipients to …
 A Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
18-99 years
All genders
Phase 2
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
 MK-7684A-006: Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC
18-100 years
All genders
Phase 3
This trial is testing MK-7684A when given in combination with chemotherapy plus radiation therapy (concurrent chemoradiotherapy or cCRT). This trial is for people with stage 3 non-small cell lung cancer (NSCLC). Receiving cCRT is part of the standard treatment for patients with stage 3 NSCLC. MK-7684A, an experimental treatment, is …
99 years and younger
All genders
To compare dependent lung ventilation (as assessed with EIT, vertical center of ventilation (CoV(v)) measure) between extremely preterm infants treated with NIV-NAVA and those treated with NS-NIPPV. To compare global ventilation homogeneity (as assessed with EIT, global inhomogeneity index (GI) measure) between extremely preterm infants treated with NIV-NAVA to those …
 Cooling to Help Injured lungs (CHILL) for  Therapeutic Hypothermia in Patients with ARDS (acute respiratory distress syndrome )
18-65 years
All genders
Phase 2
This study will analyze the potential lung protective effect of mild therapeutic hypothermia (TH), similar to that used for cardiac arrest, in ICU patients with acute respiratory distress syndrome (ARDS).
99 years and younger
All genders
This study is being done to answer the following questions: Does starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (OS) (time being alive) for patients with your type of cancer? Does additional treatment …
99 years and younger
All genders
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder for whom previous treatment was not successful or no treatment exists, to find out whether a medicine called BI 907828 helps. BI 907828 is a so-called MDM2 inhibitor that is being developed to …
18-99 years
All genders
The main purpose of this study is to determine if certain genes, hormones, or other factors predict the risk of developing lung vessel disease in patients with liver disease and whether they determine outcome. Patients in need of a liver transplant evaluation or have portopulmonary hypertension or are suspected of …
 Intramolecular Imaging with ICG (PRIME)
18-99 years
All genders
Phase 2
Interventional
The purpose of this protocol is to monitor the rate of recurrence in patients who undergo cancer surgery. Patient diagnosed with solid tumor cancers have a high rate of recurrence when surgery is a treatment. The high rates of recurrence suggest that surgeons are unable to completely detect and remove …
 Depemokimab compared with mepolizumab for relapsing or refractory EGPA on standard of care therapy
18-90 years
All genders
Phase 3
The purpose of this study is to learn more about eosinophilic granulomatosis with polyangiitis (EGPA) that returns (relapse) or has not responded to treatment, and if the investigational drug depemokimab can improve the disease.  This study is being done to help determine if depemokimab is safe and how it works …